Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study

BACKGROUND: We compared the efficacy, safety, and immunogenicity of MIL60 with reference bevacizumab as first-line treatment in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in this phase 3, randomized, double-blind study. METHODS: Patients with untreated advanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Rui, Dong, Xiaorong, Chen, Qun, Yu, Yan, Yang, Shujun, Zhang, Xiaochun, Zhang, Guojun, Pan, Yueyin, Sun, Sanyuan, Zhou, Chengzhi, Hong, Wei, Zhao, Hui, Yang, Lei, Huang, Linian, Wu, Rong, Zang, Aimin, Ma, Rui, Wu, Lin, Lv, Dongqing, Fu, Xiuhua, Han, Jianguo, Li, Wenxin, Duan, Jianchun, Wang, Kai, Jiang, Ou, Chen, Yinglan, Guo, Zhongliang, Gao, Hongjun, Wen, Juyi, Wang, Shubin, Zhao, Enfeng, Li, Gaofeng, Yue, Lu, Liang, Li, Zeng, Aiping, Wang, Xiaoshan, Zhu, Yuxi, Pan, Hongming, Dai, Zhaoxia, Feng, Weineng, Zhao, Guofang, Lin, Chuan, Li, Chong, Li, Na, Bao, Yangyi, Li, Yinyin, Su, Yanjun, Zhao, Min, Fang, Haohui, Zhu, Yulong, Zhang, Yu, Ding, Lieming, Wang, Yang, Yuan, Xiaobin, Wang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606331/
https://www.ncbi.nlm.nih.gov/pubmed/34841235
http://dx.doi.org/10.1016/j.eclinm.2021.101187

Ejemplares similares

Ejemplares similares